Fig. 1
From: A novel HVEM-Fc recombinant protein for lung cancer immunotherapy
1 mg/kg HVEM-Fc yielded the strongest tumor-inhibitory effect. Notes: A The detailed structure of HVEM-Fc; B The treatment plans for mouse lung cancer models; C-D Low dose of HVEM-Fc had the potential of anti-tumor function; E–F IHC of CD8 and CD56 in mouse tumor; G-K the optimal dose of HVEM-Fc was explored; L-O The results of RNA sequencing. The image captured at 200 × magnification